Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival BioSpaceIn a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. Clinical DataOncologyRead full story Post navigation Previous: IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacyNext: 220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
